Laurus Labs

614.50
+4.00
(0.66%)
Market Cap
33,137.10 Cr
EPS
2.98
PE Ratio
92.58
Dividend Yield
0.13 %
Industry
Healthcare
52 Week High
660.90
52 Week Low
385.45
PB Ratio
7.41
Debt to Equity
0.56
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
SELL
Analysts have suggested that investors can sell this stock
Buy
Buy+36.36 %
+36.36 %
Hold
Hold+18.18 %
+18.18 %
Sell
Sell+45.45 %
+45.45 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,699.80
#1 4,07,839.00
35.55
#1 49,887.20
12.06
#1 9,648
-18.99
45.69
6,631.50
1,76,045.50
80.38
8,184.00
0.89
1,600
23.05
64.51
1,476.90
1,19,276.70
22.62
26,520.70
14.17
4,155
30.28
46.70
3,161.10
1,06,986.00
55.56
10,785.70
11.59
1,656
10.91
42.78
1,248.20
1,04,156.70
#1 18.42
28,905.40
12.36
5,578
21.14
66.73
2,461.80
1,01,568.60
51.21
10,615.60
19.57
1,942
-10.91
48.11
924.75
93,051.50
19.92
19,831.50
13.82
3,831
-0.19
61.49
1,970.10
89,943.10
27.40
20,141.50
#1 19.94
1,936
#1 112.49
44.46
1,172.90
68,122.20
19.71
29,559.20
17.55
3,169
-0.50
47.14
30,350.00
64,491.60
45.58
6,097.20
10.80
1,201
27.83
49.13
Forecast
Actual
Growth Rate
Revenue Growth
-16.20 %
Net Income Growth
-78.89 %
Cash Flow Change
-33.02 %
ROE
-79.22 %
ROCE
-67.38 %
EBITDA Margin (Avg.)
-39.99 %

Quarterly Financial Results

Quarterly Financials
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
412
525
519
483
486
545
489
565
542
599
531
637
555
714
732
841
981
1,144
1,295
1,417
1,284
1,206
1,034
1,426
1,541
1,577
1,546
1,383
1,185
1,226
1,197
1,458
1,197
1,228
1,425
1,779
Expenses
325
408
406
358
382
426
392
443
459
513
442
523
467
575
581
647
696
765
862
940
883
858
744
1,028
1,085
1,127
1,141
1,095
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
EBITDA
87
116
112
125
104
119
97
122
83
86
89
114
88
139
150
194
285
379
433
477
401
348
291
398
456
450
405
287
170
190
184
260
174
183
295
479
Operating Profit %
21 %
21 %
20 %
24 %
20 %
21 %
18 %
21 %
15 %
13 %
17 %
18 %
15 %
19 %
20 %
23 %
29 %
33 %
33 %
33 %
31 %
29 %
28 %
28 %
30 %
28 %
26 %
21 %
14 %
15 %
15 %
17 %
14 %
15 %
20 %
24 %
Depreciation
25
26
27
28
30
30
31
35
38
40
43
44
46
48
48
46
49
51
52
54
59
63
64
66
71
82
84
87
91
93
98
102
106
108
106
110
Interest
28
25
31
17
19
20
18
23
22
25
24
18
23
26
21
21
15
14
17
22
27
22
23
31
29
40
43
53
39
42
51
51
49
53
58
56
Profit Before Tax
35
66
54
81
55
70
49
64
23
22
23
53
19
66
82
127
222
314
364
401
316
263
204
302
356
328
278
147
41
54
35
107
19
23
131
312
Tax
9
18
9
9
16
21
14
19
6
6
5
9
4
9
8
17
50
72
91
104
74
59
49
70
104
95
75
42
14
17
11
32
6
3
38
80
Net Profit
26
48
45
71
39
49
35
45
17
16
18
43
15
57
74
110
172
242
273
297
242
204
155
232
252
233
203
105
27
37
23
75
13
20
93
233
EPS in ₹
3.73
5.18
4.50
6.75
3.68
4.61
3.29
4.26
1.56
1.53
1.67
4.07
1.42
1.06
1.38
2.06
3.21
4.53
5.09
5.53
4.50
3.76
2.87
4.29
4.68
4.33
3.78
1.90
0.46
0.69
0.43
1.40
0.23
0.37
1.71
4.34

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,894
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,653
3,409
3,890
Current Assets
865
1,003
1,140
1,248
1,463
1,812
3,075
3,345
3,462
3,835
Capital Work in Progress
110
70
143
163
110
67
362
813
551
423
Investments
0
7
3
3
3
3
3
31
50
124
Other Assets
983
1,126
1,277
1,369
1,589
1,953
3,215
3,472
3,651
3,950
Total Liabilities
1,894
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
Current Liabilities
805
884
1,121
1,307
1,424
1,692
2,457
2,681
2,432
3,112
Non Current Liabilities
365
483
202
227
349
288
693
928
1,180
1,159
Total Equity
724
857
1,330
1,483
1,558
1,770
2,601
3,359
4,049
4,116
Reserve & Surplus
642
774
1,225
1,371
1,447
1,658
2,490
3,244
3,930
4,003
Share Capital
82
82
106
106
106
107
107
108
108
108

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
24
-27
-10
1
0
-1
47
27
-30
93
Investing Activities
-397
-312
-289
-384
-253
-221
-941
-915
-997
-822
Operating Activities
-65
182
332
343
298
347
733
911
994
666
Financing Activities
486
103
-54
42
-45
-128
255
30
-27
250

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
27.45 %
27.30 %
27.30 %
27.27 %
27.27 %
27.27 %
27.27 %
27.20 %
27.20 %
27.20 %
27.20 %
27.19 %
27.19 %
27.18 %
27.18 %
27.62 %
27.62 %
FIIs
0.00 %
0.04 %
0.04 %
0.02 %
0.02 %
0.02 %
0.00 %
0.02 %
0.02 %
0.00 %
0.00 %
0.00 %
25.97 %
25.67 %
26.08 %
25.56 %
25.52 %
DIIs
2.06 %
2.40 %
2.11 %
2.77 %
3.51 %
4.77 %
8.98 %
9.51 %
9.74 %
10.14 %
10.71 %
10.77 %
11.77 %
13.56 %
13.05 %
12.74 %
11.77 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
34.17 %
34.18 %
32.91 %
32.87 %
31.15 %
28.42 %
27.96 %
28.95 %
28.49 %
28.26 %
26.49 %
25.01 %
23.95 %
22.68 %
22.67 %
22.72 %
23.65 %
Others
36.32 %
36.07 %
37.65 %
37.08 %
38.05 %
39.53 %
35.80 %
34.32 %
34.55 %
34.39 %
35.60 %
37.03 %
11.12 %
10.91 %
11.03 %
11.36 %
11.44 %
No of Share Holders
2,35,836
2,99,257
3,94,053
4,67,419
4,27,465
4,07,186
3,90,695
4,23,931
4,18,615
4,17,977
4,02,640
3,82,880
3,56,830
3,24,059
3,09,063
2,92,214
2,92,905

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.5 1.5 1.5 2.5 2 2 2 0.8 0.00
Dividend Yield (%) 0.00 1.49 1.88 2.31 0.69 0.34 0.67 0.51 0.13 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
26 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jun 2025 606.00 610.70
09 May 2025 DIVIDEND Dividend
₹ 0.80 /share
09 May 2025 650.45 586.00
24 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Apr 2025 564.25 650.45
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Jan 2025 611.75 585.15
06 Nov 2024 DIVIDEND Dividend
₹ 0.40 /share
06 Nov 2024 449.35 489.25
24 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Oct 2024 480.30 449.35
11 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Jul 2024 434.40 472.50
08 May 2024 DIVIDEND Dividend
₹ 0.40 /share
08 May 2024 434.40 429.45
02 Nov 2023 DIVIDEND Dividend
₹ 0.40 /share
02 Nov 2023 396.40 358.90
10 May 2023 DIVIDEND Dividend
₹ 1.20 /share
10 May 2023 300.05 334.30
04 Nov 2022 DIVIDEND Dividend
₹ 0.80 /share
03 Nov 2022 526.20 477.75
11 May 2022 DIVIDEND Dividend
₹ 1.20 /share
10 May 2022 578.80 525.10
18 Nov 2021 DIVIDEND Dividend
₹ 0.80 /share
17 Nov 2021 574.90 484.00
12 May 2021 DIVIDEND Dividend
₹ 0.80 /share
11 May 2021 474.45 491.75
09 Feb 2021 DIVIDEND Dividend
₹ 0.40 /share
08 Feb 2021 366.20 356.95

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Compliances-Reg.24(A)-Annual Secretarial Compliance10 days ago
Board Meeting Outcome for Convening Of 20Th Annual General Meeting (AGM) Of The Company On Thursday June 26 2025 Through Video Conferencing/Other Audio Visual MeansMay 15, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 09, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptApr 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationApr 24, 2025
Corporate Action-Board approves DividendApr 24, 2025
Board Meeting Outcome for Board Meeting Outcome - 24.04.2025Apr 24, 2025
Results - Year Ended March 31 2025Apr 24, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 10, 2025
Board Meeting Intimation for Consideration Of Audited Financial Results For The Quarter And Year Ended March 31 2025 And Payment Of 2Nd Interim Dividend For FY 2024-25Apr 10, 2025
Corrigendum To Intimation Of Grant Of Stock Options To The Eligible Employees Dated 28.03.2025Mar 28, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 28, 2025
Intimation Of Re-Appointment Of Executive Directors Of The Company Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 28, 2025
Intimation Of Grant Of Stock Options To The Eligible EmployeesMar 28, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 15, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 31, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 31, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 27, 2025
Rumour verification - Regulation 30(11)Jan 27, 2025
Clarification sought from Laurus Labs LtdJan 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Integrated Filing (Financial)Jan 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Results For The Quarter Ended 31.12.2024Jan 24, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 22, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 31, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 06, 2024
Announcement under Regulation 30 (LODR)-AcquisitionDec 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 27, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 29, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 25, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 24, 2024
General UpdatesOct 24, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 24, 2024

Technical Indicators

RSI(14)
Neutral
55.71
ATR(14)
Less Volatile
16.40
STOCH(9,6)
Neutral
48.59
STOCH RSI(14)
Overbought
96.92
MACD(12,26)
Bullish
1.13
ADX(14)
Weak Trend
12.13
UO(9)
Bearish
50.75
ROC(12)
Uptrend And Accelerating
3.23
WillR(14)
Overbought
-13.18

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
WhiteOak Capital Mid Cap Fund Direct - Growth
305022
0.63%
0.63%
0.63%
Apr 2025
Sundaram Long Term Micro Cap Tax Advantage Fund Series V Direct - Growth
12887
2.78%
-0.62%
-0.24%
Apr 2025
SBI Healthcare Opportunities Fund Direct Plan-Growth
1500000
2.47%
-0.59%
-0.24%
Apr 2025
UTI Multi Asset Allocation Fund Direct-Growth
441920
0.48%
0.48%
0.48%
Apr 2025
JM Arbitrage Fund Direct-Growth
6800
0.21%
-0.46%
-0.42%
Apr 2025
WhiteOak Capital Multi Cap Fund Direct - Growth
130767
0.46%
0.46%
0.46%
Apr 2025
Tata India Pharma & Healthcare Fund Direct-Growth
455000
2.25%
-0.37%
-0.16%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.35%
-0.30%
Apr 2025
DSP Equity Opportunities Fund Direct Plan-Growth
1017870
0.43%
-0.30%
-0.26%
Apr 2025
DSP ELSS Tax Saver Fund Direct Plan-Growth
1269245
0.46%
-0.29%
-0.25%
Apr 2025
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
202657
3.82%
0.27%
1.46%
Apr 2025
Baroda BNP Paribas Arbitrage Fund Direct - Growth
39100
0.23%
0.23%
0.23%
Apr 2025
ITI Pharma and Healthcare Fund Direct - Growth
35017
0.97%
0.23%
0.97%
Apr 2025
Taurus Ethical Fund Direct-Growth
0
0.00%
-0.22%
-0.50%
Apr 2025
WhiteOak Capital Large & Mid Cap Fund Direct - Growth
51993
0.20%
0.20%
0.20%
Apr 2025
Kotak Quant Fund Direct - Growth
174185
1.52%
-0.19%
-0.06%
Apr 2025
Invesco India Arbitrage Fund Direct-Growth
1606500
0.48%
0.18%
0.22%
Apr 2025
HSBC Arbitrage Fund Direct-Growth
758200
1.96%
-0.18%
0.10%
Apr 2025
Kotak Nifty Smallcap 50 Index Fund Direct - Growth
75962
3.87%
-0.17%
0.19%
Apr 2025
Axis Nifty Smallcap 50 Index Fund Direct-Growth
286966
3.87%
-0.17%
0.20%
Apr 2025
Aditya Birla Sun Life Nifty Smallcap 50 Index Fund Direct-Growth
135951
3.87%
-0.17%
0.20%
Apr 2025
Union Active Momentum Fund Direct-Growth
148533
2.13%
0.16%
0.37%
Apr 2025
DSP Business Cycle Fund Direct - Growth
153868
0.90%
-0.15%
-0.39%
Apr 2025
Franklin India Prima Fund Direct-Growth
972358
0.50%
-0.15%
-0.43%
Apr 2025
Kotak Equity Arbitrage Fund Direct-Growth
3213000
0.31%
0.15%
0.21%
Apr 2025

About Laurus Labs

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
Listing Date
19 Dec, 2016(8 Years, 41 days)
Chairperson NameRavindranath Kancherla